Cargando…

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients

BACKGROUND/AIMS: Pemafibrate is a selective peroxisome proliferator-activated receptor α modulator that improves serum alanine aminotransferase (ALT) in dyslipidemia patients. Pemafibrate was reported to reduce ALT in non-alcoholic fatty liver disease (NAFLD) patients, but efficacy was not clearly e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugimoto, Ryosuke, Iwasa, Motoh, Eguchi, Akiko, Tamai, Yasuyuki, Shigefuku, Ryuta, Fujiwara, Naoto, Tanaka, Hideaki, Kobayashi, Yoshinao, Ikoma, Jiro, Kaito, Masahiko, Nakagawa, Hayato
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941328/ https://www.ncbi.nlm.nih.gov/pubmed/36824614 http://dx.doi.org/10.3389/fmed.2023.1073025

Ejemplares similares

Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans
por: Tamai, Yasuyuki, et al.
Publicado: (2022)

Update on blood‐based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience
por: Iwasa, Motoh, et al.
Publicado: (2021)

Elevation of enterococcus-specific antibodies associated with bacterial translocation is predictive of survival rate in chronic liver disease
por: Iwasa, Motoh, et al.
Publicado: (2022)

Serum copper, zinc and metallothionein serve as potential biomarkers for hepatocellular carcinoma
por: Tamai, Yasuyuki, et al.
Publicado: (2020)

The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage
por: Eguchi, Akiko, et al.
Publicado: (2022)

Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab
por: Shigefuku, Ryuta, et al.
Publicado: (2022)

Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites
por: Shigefuku, Ryuta, et al.
Publicado: (2021)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Serum Liver‐Type Fatty Acid–Binding Protein Is a Possible Prognostic Factor in Human Chronic Liver Diseases From Chronic Hepatitis to Liver Cirrhosis and Hepatocellular Carcinoma
por: Eguchi, Akiko, et al.
Publicado: (2019)

The Associations between Circulating Bile Acids and the Muscle Volume in Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
por: Kobayashi, Yoshinao, et al.
Publicado: (2017)

Successful endoscopic cyanoacrylate injection therapy for ruptured duodenal varices immediately after balloon‐occluded retrograde transvenous obliteration
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Effects of endoscopic injection sclerotherapy for esophagogastric varices on portal hemodynamics and liver function
por: Shigefuku, Ryuta, et al.
Publicado: (2022)

A Rare Presentation of Intraperitoneal Ectopic Varices Rupture
por: Shigefuku, Ryuta, et al.
Publicado: (2020)

A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis
por: Eguchi, Akiko, et al.
Publicado: (2022)

Neutrophil gelatinase‐associated lipocalin level is a prognostic factor for survival in rat and human chronic liver diseases
por: Yoshikawa, Kyoko, et al.
Publicado: (2017)

Branched-Chain Amino Acid Supplementation Reduces Oxidative Stress and Prolongs Survival in Rats with Advanced Liver Cirrhosis
por: Iwasa, Motoh, et al.
Publicado: (2013)

Complement complex 1 subunit q‐mediated hepatic stellate cell activation with connective tissue growth factor elevation is a prognostic factor for survival in rat and human chronic liver diseases
por: Eguchi, Akiko, et al.
Publicado: (2022)

Circulating Extracellular Vesicles and Their miR “Barcode” Differentiate Alcohol Drinkers With Liver Injury and Those Without Liver Injury in Severe Trauma Patients
por: Eguchi, Akiko, et al.
Publicado: (2019)

Protein Composition of Circulating Extracellular Vesicles Immediately Changed by Particular Short Time of High-Intensity Interval Training Exercise
por: Kobayashi, Yoshinao, et al.
Publicado: (2021)

Development of a New Index to Distinguish Hepatic Encephalopathy through Automated Quantification of Globus Pallidal Signal Intensity Using MRI
por: Tamai, Yasuyuki, et al.
Publicado: (2022)

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Utility of the SARC-F Questionnaire for Sarcopenia Screening in Patients with Chronic Liver Disease: A Multicenter Cross-Sectional Study in Japan
por: Hanai, Tatsunori, et al.
Publicado: (2021)

Unidentified virus-like particles are detected in plasmas with elevated ALT levels: are they significant of etiological agent(s) of non-B, non-C hepatitis?
por: Kaito, Masahiko, et al.
Publicado: (2007)

Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease
por: Shinozaki, Satoshi, et al.
Publicado: (2020)

Combination Therapy Using Pemafibrate and Dapagliflozin for Metabolic Dysfunction-associated Fatty Liver Disease
por: Imamura, Teruhiko, et al.
Publicado: (2022)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Recurrent hepatocellular carcinoma with osteoclast-like giant cells: a case report
por: Tsukimoto, Mone, et al.
Publicado: (2022)

Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
por: Morishita, Asahiro, et al.
Publicado: (2022)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma
por: Tamai, Yasuyuki, et al.
Publicado: (2023)

Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease
por: Ishikawa, Toru, et al.
Publicado: (2023)

Clinico‐histological and molecular features of hepatocellular carcinoma from nonalcoholic fatty liver disease
por: Fujiwara, Naoto, et al.
Publicado: (2023)

Clinical value of liver and spleen shear wave velocity in predicting the prognosis of patients with portal hypertension
por: Zhang, Yan, et al.
Publicado: (2017)

Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population
por: Kirino, Sakura, et al.
Publicado: (2023)

Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients
por: Shinozaki, Satoshi, et al.
Publicado: (2022)

Factors other than fibrosis that increase measured shear wave velocity
por: Naganuma, Hiroko, et al.
Publicado: (2022)

Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease
por: Gharib, Ahmed M., et al.
Publicado: (2017)

Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy
por: Kanno, Kotaro, et al.
Publicado: (2022)

RE: Liver Shear-Wave Velocity to Diagnose Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B
por: Ozturker, Coskun, et al.
Publicado: (2016)

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nhse13qht50q879vg9b14akeim